Characterization of human cytochrome P450 enzymes involved in the metabolism of cyamemazine

European Journal of Pharmaceutical Sciences

Volumn 32, Issue 4-5, 2007, Pages 357-366

  Arbus, Christophe ^a   Benyamina, Amine ^b   Llorca, Pierre Michel ^c   Baylé, Franck ^d   Bromet, Norbert ^e   Massiere, Frédéric ^f   Garay, Ricardo P ^g   Hameg, Ahcène ^h  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b HÔPITAL PAUL BROUSSE   (France)

^c UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^d INSERM   (France)

^e Biotec Centre   (France)

^f Biopredic   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h SANOFI   (France)

Author keywords

Antipsychotics; Cyamemazine; CYP; Metabolism

Indexed keywords

ANXIOLYTIC AGENT; CHLORPROMAZINE; CHLORZOXAZONE; COUMARIN; CYAMEMAZINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; DRUG METABOLITE; FURAFYLLINE; KETOCONAZOLE; LIVER ENZYME; MEPHENYTOIN; NEUROLEPTIC AGENT; NIFEDIPINE; PACLITAXEL; PHENACETIN; QUINIDINE; SULFAPHENAZOLE; TOLBUTAMIDE;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEMETHYLATION; DRUG DEGRADATION; DRUG DETOXIFICATION; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME ACTIVITY; ENZYME ANALYSIS; HUMAN; HUMAN CELL; HYDROXYLATION; IN VITRO STUDY; INCUBATION TIME; LIQUID CHROMATOGRAPHY; LIVER CELL; LIVER MICROSOME; MASS SPECTROMETRY; OXIDATION; PRIORITY JOURNAL;

CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME ACTIVATION; HUMANS; LIVER; METABOLIC DETOXICATION, DRUG; MICROSOMES, LIVER; MOLECULAR STRUCTURE; PHENOTHIAZINES; RECOMBINANT PROTEINS; TANDEM MASS SPECTROMETRY;

EID: 35948957811     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2007.09.003     Document Type: Article

References (18)

1. Bourin M., Dailly E., and Hascoet M. Preclinical and clinical pharmacology of cyamemazine: anxiolytic effects and prevention of alcohol and benzodiazepine withdrawal syndrome. CNS Drug Rev. 10 (2004) 219-229
2. Bradford M.A. Rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 22 (1976) 248-256
3. Busby W.F.J., Ackermann J.M., and Crespi C.L. Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450. Drug Metab. Dispos. 27 (1999) 246-249
4. Caveroand I., and Crumb W. ICH S7B draft guideline on the non-clinical strategy for testing delayed cardiac repolarisation risk of drugs: a critical analysis. Expert Opin. Drug Saf. 4 (2005) 509-530
5. Clarke S.E. In vitro assessment of human cytochrome P450. Xenobiotica 12 (1998)
6. Crespi C.L. Effect of salt concentration on the activity of liver microsomal and cDNA-expressed human cytochromes P450. Proceedings of 12th International Symposium on micrososmes and drug oxidation (ISMDO). Montpellier, France (1998)
7. Cresteil T., Monarrat B., Alvinerie P., Treluyer J.M., Viera I., and Wright M. Taxol metabolism by human liver microsomes: identification f cytochrome P450 isoenzymes involved in its biotransformation. Cancer Res. 54 (1994) 386-392
8. Crumb W., Llorca P.-M., Lancon C., Thomas G.P., Garay R.P., and Hameg A. Effects of cyamemazine on hERG, INa, ICa, Ito, Isus and IK1 channel currents, and on the QTc interval in guinea pigs. Eur. J. Pharmacol. 532 (2006) 270-278
9. Dekant W., Frischmann C., and Speerschneider P. Sex, organ and species specific bioactivation of chloromethane by cytochrome P450 2E1. Xenobiotica 25 (1995) 1259-1265
10. Distlerath L., Reilly P.E., Martin M.V., Davis G.G., Wilkinson G.R., and Guengerich F. Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 260 (1985) 9057-9065
11. Greenleeand W., and Poland A. An improved assay of 7-ethoxycoumarin O-deethylase activity: induction of hepatic enzyme activity in C57BL/6J and DBA/2J mice by phenobarbital, 3-methylcholanthrene and 2,3,7,8-tetrachlordibeno-p-dioxin. J. Pharmacol. Exp. Ther. 205 (1978) 596-605
12. Guengerich P.P., Martin M.V., Beaune P.H., Kremers P., Wolf T., and Waxman D.J. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 261 (1986) 5051-5060
13. Gury C., Canceil O., and Iaria P. Antipsychotiques et sécurité cardio-vasculaire: données actuelles sur les allongements de l'intervalle QT et le risque d'arythmies ventriculaires. L'Encéphale 26 (2000) 62-72
14. Gury C., Fabre C., Hameg A., Simo E., Surugue J., Garay R.P., and Welcomme N. Prescription d'antipsychotiques en milieu hospitalier spécialisé. l'Information Psychiatrique 82 (2006) 503-509
15. Miners J.O., Smith K.J., Robson R.A., Mac Manus M.E., Veronese M.E., and Birkett D.J. Tolbutamide hydroxylation by human liver microsomes. Biochem. Pharmacol. 37 (1988) 1137-1144
16. Omuraand T., and Sato R. The carbon monoxide-binding pigment of liver microsomes. J. Biol. Chem. 239 (1964) 2370-2378
17. Pelkonen O., Mäenpää J., Taavitssainen P., Rautio A., and Raunio H. Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica 12 (1998) 1203-1253
18. Rendicand S., and Di Carlo F.G. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers and inhibitors. Drug Metab. Rev. 29 (1997) 413-580